<DOC>
	<DOCNO>NCT00224458</DOCNO>
	<brief_summary>To characterize risk ( safety tolerability ) , effectiveness ( continued viral load suppression CD4 change ) , benefit ( safety , tolerability , adherence , general satisfaction treatment regimen QoL ) , switch Combivir ( BID ) / efavirenz ( QD ) regimen QD regimen Truvada/efavirenz .</brief_summary>
	<brief_title>Combination Efavirenz Truvada - COMET Study</brief_title>
	<detailed_description>The objective study characterize risk ( safety tolerability ) , effectiveness ( continued viral load suppression CD4 change ) , benefit ( safety , tolerability , adherence , general satisfaction treatment regimen QoL ) , switch Combivir ( BID ) / efavirenz ( QD ) regimen QD regimen Truvada/efavirenz .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Adult ( great 18 year ) male nonpregnant female HIV1 infect patient regardless race ethnicity . On stable antiretroviral regimen consist efavirenz QD Combivir BID great 8 week . Plasma HIV 1 RNA less 400 copies/mL ( Roche Amplicor HIV 1 Monitor Test Version 1.5 Ultrasensitive method ) . Currently experience adverse clinical laboratory effect associate Combivir and/or might benefit simplified , oncedaily antiretroviral treatment regimen regardless Combivir tolerability status . Adequate renal function define calculated creatinine clearance ( CLCr ) great equal 50 mL/min accord CockcroftGault formula : Male : ( 140 age year ) x ( wt kg ) divide 72 x ( serum creatinine mg/dL ) = CLCr ( mL/min . Female : ( 140 age year ) x ( wt kg ) divide 72 x ( serum creatinine mg/dL ) x 0.85 = CLCr ( mL/min ) . Negative serum pregnancy test ( female childbearing potential ) . Willingness use effective contraception ( barrier coil method ) male female study drug 30 day follow study drug completion . Life expectancy less 1 year . The ability understand sign write informed consent form , must obtain prior initiation study procedure . A new AIDS defining condition diagnose ( exception CD4 criterion ) within 30 day baseline . Clinically significant laboratory value would preclude prescribe antiretroviral therapy , opinion investigator . Receiving ongoing therapy follow ( administration follow medication must discontinue least 30 day prior Baseline visit duration study period ) : Nephrotoxic agent ( aminoglycoside antibiotic , IV amphotericin B , cidofovir , cisplatin , foscarnet , IV pentamidine , agent significant nephrotoxic potential ) : Adefovir dipivoxil Probenecid Systemic chemotherapeutic agent ( i.e. , cancer treatment medication ) Systemic corticosteroid Interleukin 2 ( IL 2 ) Investigational agent ( except upon approval Gilead ) . Drugs interact efavirenz : dihydroergotamine ergotamine ergonovine methylergonovine midazolam triazolam cisapride rifampin Pregnant lactating patient . Evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication . Current alcohol substance abuse judge investigator potentially interfere patient adherence . Malignancy cutaneous Kaposi 's sarcoma ( KS ) basal cell carcinoma . Patients biopsyconfirmed cutaneous KS eligible , must receive systemic therapy KS within 30 day baseline anticipate require systemic therapy study . Active , serious infection ( HIV 1 infection ) require parenteral antibiotic therapy within 15 day prior screen . Prior history significant renal bone disease . Any clinical condition prior therapy , opinion investigator , would make patient unsuitable study unable comply dose requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV-1</keyword>
</DOC>